Lifeward shares surge 39.27% intraday after Humana Medicare Advantage approves ReWalk 7 reimbursement.

Lifeward surged 39.27% intraday following the announcement that Humana Medicare Advantage Plan granted prior authorization for its ReWalk 7 Personal Exoskeleton. This marks the second major Medicare Advantage provider, after UnitedHealthcare in November, to approve coverage for the device, now benefiting 47% of Medicare Advantage enrollees. The approval is expected to enhance patient access, strengthen reimbursement predictability, and drive revenue growth, as emphasized by CEO Mark Grant. The news aligns with CMS’s 2024 formal reimbursement pathway for exoskeletons, accelerating payer adoption and validating the technology’s clinical value. The stock’s sharp intraday rise reflects optimism over expanded market access and improved cash flow dynamics, positioning Lifeward for scalable U.S. market growth.